<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">92741</article-id>
<article-id pub-id-type="doi">10.7554/eLife.92741</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92741.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell Biology</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Cancer Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>TIPE drives a cancer stem-like phenotype by promoting glycolysis via PKM2/HIF-1α axis in melanoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Tian</surname>
<given-names>Maojin</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yang</surname>
<given-names>Le</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhao</surname>
<given-names>Ziqian</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Jigang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Lianqing</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yin</surname>
<given-names>Qingqing</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lou</surname>
<given-names>Yunwei</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Du</surname>
<given-names>Jianxin</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9311-1927</contrib-id>
<name>
<surname>Zhao</surname>
<given-names>Peiqing</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Center of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University</institution>, Zibo, 255036, PR <country>China</country></aff>
<aff id="a2"><label>2</label><institution>Shandong First Medical University</institution>, Jinan,250117, PR <country>China</country></aff>
<aff id="a3"><label>3</label><institution>The Second Medical College, Xinjiang Medical University</institution>, Urumqi, 830092, PR <country>China</country></aff>
<aff id="a4"><label>4</label><institution>School of Laboratory Medicine, Xinxiang Medical University</institution>, Xinxiang,453003, PR <country>China</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Postovit</surname>
<given-names>Lynne-Marie</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Queens University</institution>
</institution-wrap>
<city>Kingston</city>
<country>Canada</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>El-Deiry</surname>
<given-names>Wafik S</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>Brown University</institution>
</institution-wrap>
<city>Providence</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>#</label><p>Contributed equally</p></fn>
<corresp id="cor1"><label>*</label>Correspondence to: Peiqing Zhao, Center of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, China, 54 Gongqingtuan Xi Road, Zibo 255036, PR China. Jianxin Du, Center of Translational Medicine, Zibo Central Hospital Affiliated to Binzhou Medical University, Zibo, China, 54 Gongqingtuan Xi Road, Zibo 255036. Tel: +86 533 2365217 Fax: +86 533 2360819 E-mail: <email>bzjzzpq@sdu.edu.cn</email> or <email>bzjzzpq@163.com</email> (Peiqing Zhao); <email>jianxindu2005@126.com</email> (Jianxin Du)</corresp>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-01-24">
<day>24</day>
<month>01</month>
<year>2024</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP92741</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-11-15">
<day>15</day>
<month>11</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-11-16">
<day>16</day>
<month>11</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.11.14.567124"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Tian et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Tian et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-92741-v1.pdf"/>
<abstract>
<title>Abstract</title><p>TIPE (TNFAIP8) has been identified as an oncogene and participates in tumor biology. However, how its role in the metabolism of tumor cells during melanoma development remains unclear. Here, we demonstrated that TIPE promoted glycolysis by interacting with pyruvate kinase M2 (PKM2) in melanoma. We found that TIPE induced PKM2 dimerization, thereby facilitating its translocation from the cytoplasm to the nucleus. TIPE-mediated PKM2 dimerization consequently promoted HIF-1α activation and glycolysis, which contributed to melanoma progression and increased its stemness features. Notably, TIPE specifically phosphorylated PKM2 at Ser 37 in an ERK-dependent manner. Consistently, the expression of TIPE was positively correlated with the levels of PKM2 Ser37 phosphorylation and cancer stem cell markers in melanoma tissues from clinical samples and tumor bearing mice. In summary, our findings indicate that the TIPE/PKM2/HIF-1α signaling pathway plays a pivotal role in promoting cancer stem cell properties by facilitating the glycolysis, which would provide a promising therapeutic target for melanoma intervention.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>TIPE</kwd>
<kwd>Glycolysis</kwd>
<kwd>PKM2</kwd>
<kwd>HIF-1α</kwd>
<kwd>Melanoma</kwd>
</kwd-group>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Melanoma is derived from the aberrant growth of melanocytes and is classified into several subgroups such as cutaneous melanoma (CM), uveal melanoma (UM), and mucosal melanoma (MM), based on its tissue locations(<xref ref-type="bibr" rid="c13">Han et al., 2021</xref>). Cutaneous melanoma (CM) is the major subgroup of melanoma. Accumulating evidence has revealed that metabolic reprogramming contributes to the tumorigenesis and progression of melanoma. Owing to its low incidence rate, targeting metabolism might be a promising therapeutic approach for the treatment of melanoma and offers a deeper understanding of its pathobiology(<xref ref-type="bibr" rid="c2">Brunner and Finley, 2022</xref>; <xref ref-type="bibr" rid="c10">Faubert et al., 2020</xref>). However, melanoma-altered metabolic reprogramming remains poorly understood.</p>
<p>The Warburg effect, also known as aerobic glycolysis, is a part of metabolic reprogramming. It increases lactate levels regardless of oxygen availability in tumor cells, providing cancer cell tumorigenicity, progression, and chemoresistance(<xref ref-type="bibr" rid="c12">Guo et al., 2022</xref>). Pyruvate kinase isoform M2 (PKM2) is the key enzyme that irreversibly converts phosphoenolpyruvate (PEP) to pyruvate in the last step of glycolysis (<xref ref-type="bibr" rid="c17">Li et al., 2016</xref>; <xref ref-type="bibr" rid="c19">Liu et al., 2021</xref>). It is shifted between catalytically inactive dimeric and active tetrameric forms, and the PKM2 dimer predominantly serves as a key glycolytic enzyme that provides advantages for tumor progression due to the Warburg effect(<xref ref-type="bibr" rid="c18">Liu et al., 2017</xref>). Post-translational modifications of PKM2, such as FGFR1-mediated Tyr105 phosphorylation and ERK1/2-dependent Ser37 phosphorylation, can promote PKM2 from a tetrameric to dimeric form, accelerating its translocation into the nucleus (<xref ref-type="bibr" rid="c5">Christofk et al., 2008</xref>; <xref ref-type="bibr" rid="c17">Li et al., 2016</xref>). In the nucleus, PKM2 acts as a protein kinase that phosphorylates STAT3(<xref ref-type="bibr" rid="c3">Chen et al., 2022a</xref>; <xref ref-type="bibr" rid="c9">Dhanesha et al., 2022</xref>) and Histone H3(<xref ref-type="bibr" rid="c26">Niu et al., 2020</xref>). Interestingly, nuclear PKM2 also functions as a coactivator for several transcription factors, such as HIF-1α(<xref ref-type="bibr" rid="c21">Luo et al., 2011</xref>; <xref ref-type="bibr" rid="c34">Wang et al., 2014</xref>) or Oct4(<xref ref-type="bibr" rid="c39">Yang et al., 2018</xref>), by which regulates metabolic gene transcription and promotes tumorigenesis or sustains cancer stem cell populations. Furthermore, HIF-1α is constitutively activated in melanoma under both normal and hypoxic conditions and is accompanied by increased glycolysis(<xref ref-type="bibr" rid="c8">D’Aguanno et al., 2021</xref>; <xref ref-type="bibr" rid="c22">Malekan et al., 2021</xref>). Therefore, the precise mechanisms underlying PKM2 activity regulation and its function as an HIF-1α coactivator might provide a molecular basis for the melanoma targeted therapy.</p>
<p>The tumor necrosis factor alpha-induced protein 8 (TNFAIP8, TIPE) family is composed of four members: TIPE, TIPE1, TIPE2, and TIPE3(<xref ref-type="bibr" rid="c37">Yang et al., 2022</xref>). Accumulating evidence suggests that TIPE is strongly associated with the development of various cancers by affecting cell proliferation, apoptosis, invasion, and metastasis(<xref ref-type="bibr" rid="c11">Goldsmith et al., 2017</xref>; <xref ref-type="bibr" rid="c24">Niture et al., 2018</xref>). Therefore, TIPE is broadly considered pro-cancerous(<xref ref-type="bibr" rid="c30">Padmavathi et al., 2018</xref>). However, we previous revealed that TIPE functions as a tumor suppressor in colitis and colitis-associated colon cancer(<xref ref-type="bibr" rid="c20">Lou et al., 2022</xref>), indicating that TIPE might serve a multifarious function in malignancies. Hitherto, the role of TIPE in melanoma remains unclear. In this study, we revealed that TIPE-mediated PKM2 Ser37 phosphorylation accelerates PKM2 translocation from the cytoplasm to the nucleus, thereby elevating its binding ability to HIF-1α and hypoxia response elements (HREs), thus promoting metabolic reprogramming. TIPE-mediated metabolic reprogramming can confer tumorigenesis and stem-like phenomena to melanoma cells. This process represents an important regulator of the TIPE family switching between oxidative phosphorylation and aerobic glycolysis, paving the way for cancer-specific metabolism in response to low-oxygen challenge.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>TIPE increases aerobic glycolysis in melanoma cells</title>
<p>To characterize how TIPE performs biological functions in melanoma, we examined its expression levels in melanoma cell lines. The results showed that A375 and A875 cells had relatively higher TIPE expression than G361 and MM96L cells. Therefore, we downregulated TIPE expression in A375 cells and overexpressed TIPE in G361 cells to perform further experiments (<bold>Fig.S1</bold>). Furthermore, we demonstrated that TIPE promotes melanoma tumorigenesis both <italic>in vitro</italic> and <italic>in vivo</italic>(<bold>Fig.S2</bold>).</p>
<p>Consequently, we performed RNA sequencing analysis by overexpressing TIPE in G361 cells (<bold><xref rid="fig1" ref-type="fig">Fig. 1A</xref></bold>) to examine the underlying mechanisms involved in the progression of melanoma. The results revealed that the overexpression of TIPE dramatically promoted glycolysis metabolites and the HIF-1α pathway (<bold><xref rid="fig1" ref-type="fig">Fig. 1B, C</xref></bold>). Since metabolic reprogramming, especially aerobic glycolysis, is tightly dependent on the HIF-1α pathway(<xref ref-type="bibr" rid="c1">Baik et al., 2019</xref>), we assumed that TIPE promotes melanoma progression might via the regulation of metabolic reprogramming. Therefore, we performed a metabolomic analysis after interfering with TIPE in A375 cells. Interestingly, the results indicated that the aerobic glycolysis pathway, including pyruvate and lactate, was significantly inhibited in melanoma cells after TIPE silencing (<bold><xref rid="fig1" ref-type="fig">Fig. 1D</xref></bold>), confirming that TIPE facilitates glycolytic metabolism in melanoma. Consequently, ATPase activity, lactate secretion, and ATP content assays were performed to further confirm TIPE-induced glycolytic changes. The results demonstrated that TIPE decreased ATPase activity and ATP content while promoting lactate production (<bold><xref rid="fig1" ref-type="fig">Fig. 1E-G</xref></bold>). Additionally, we measured the extracellular acidification rate (ECAR) after the overexpression or downregulation of TIPE using a Seahorse Bioscience Flux Analyzer. The results also revealed that TIPE promoted glycolysis and glycolytic capacity in melanoma cells (<bold><xref rid="fig1" ref-type="fig">Fig. 1H-K</xref></bold>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Effect of TIPE on melanoma cell glycolysis.</title>
<p><bold>A, B.</bold> Transcriptomics analysis by unsupervised hierarchical clustering and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that TIPE increased glycolysis and HIF-1α pathways. <bold>C.</bold> GSEA analysis of glycolysis showed that TIPE enhanced glycolysis compared to the control. <bold>D.</bold> Untargeted metabolomics analysis indicated that interfering with TIPE decreased the glycolysis pathway. <bold>E-G.</bold> TIPE decreases ATPase activity and ATP content and increases lactate levels. <bold>H, I.</bold> Overexpression of TIPE promotes glycolysis and glycolytic capacity according to ECAR analysis. <bold>J, K.</bold> Interfering with TIPE decreased glycolysis and glycolytic capacity using ECAR analysis. <bold>L.</bold> TIPE significantly activated HRE activity. *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01; ***<italic>P</italic>&lt;0.001.</p></caption>
<graphic xlink:href="567124v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Furthermore, we investigated whether TIPE affected HIF-1α transcriptional activity or its expression levels. The results demonstrated that TIPE increased the expression of HIF-1α at both mRNA and protein levels(<bold>Fig. S3</bold>). Interestingly, TIPE can dramatically activate the hypoxia response element(HRE) reporter activity, with which HIF-1α is more prone to recognize the specific DNA motif to regulate metabolic gene transcription(<xref ref-type="bibr" rid="c4">Chen et al., 2022b</xref>)(<bold><xref rid="fig1" ref-type="fig">Fig. 1L</xref></bold>).</p>
<p>Collectively, above results demonstrate that TIPE plays a crucial role in promoting melanoma glycolysis. However, the impact of TIPE on the Warburg effect by regulating HIF-1α activity requires further investigation.</p>
</sec>
<sec id="s2b">
<title>TIPE interacts with PKM2, promotes its dimerization and nuclear import</title>
<p>To further study the functions of TIPE in melanoma, we used the Co-IP/MS method to bait the potential binding partners of TIPE (the candidate interacting proteins of TIPE are listed in <bold>Table S1</bold>). Interestingly, we found that PKM2, the key enzyme in aerobic glycolysis, might be a new partner of TIPE in melanoma (<bold><xref rid="fig2" ref-type="fig">Fig. 2A</xref></bold>) (<bold>Fig. S4</bold>). Next, we performed Co-IP assays to confirm the interactions between TIPE and PKM2. The results revealed that exogenously overexpressed Flag-tagged PKM2 interacted with exogenously overexpressed HA-tagged TIPE (<bold><xref rid="fig2" ref-type="fig">Fig. 2B, C</xref></bold>). Furthermore, endogenous interactions between PKM2 and TIPE were confirmed in the A375 cells (<bold><xref rid="fig2" ref-type="fig">Fig. 2D, E</xref></bold>). GST-pull down assays demonstrated that TIPE directly bound to PKM2 <italic>in vitro</italic> (<bold><xref rid="fig2" ref-type="fig">Fig. 2F</xref></bold>). Moreover, we performed Doulink assay to further demonstrate their endogenous interactions. The results also showed that endogenous interactions between TIPE and PKM2 were confirmed in G361 cells (<bold><xref rid="fig2" ref-type="fig">Fig. 2G</xref></bold>). Based on these interactions, we identified the binding regions between TIPE and PKM2. We generated four fragments of PKM2, including amino acids 1-390(NA1BA2), 45-390(A1BA2), 1-219(NA1B) and 220-390(A2), based on their structural domains (<bold><xref rid="fig2" ref-type="fig">Fig. 2H</xref></bold>). The results showed that except for the A2 domain, the NA1BA2, A1BA2, and NA1B domains of PKM2 were necessary for its interaction with TIPE (<bold><xref rid="fig2" ref-type="fig">Fig. 2I</xref></bold>). Finally, the TIPE protein was divided into two fragments, including amino acids 1-100 (M1) and 101-198 (M2). The data showed that the amino acids 1-100(M1) and 101-198(M2) of TIPE interacted with PKM2 (<bold><xref rid="fig2" ref-type="fig">Fig. 2J</xref></bold>). Taken together, these data revealed that TIPE interacts with PKM2.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>TIPE interacts with PKM2 to govern its nuclear import in a dimeric form dependent manner.</title>
<p><bold>A.</bold> Co-IP/MS analysis demonstrated that PKM2 interacted with TIPE in A375 cells. <bold>B, C.</bold> Immunoprecipitation (IP) and western blot analysis of the exogenous TIPE/PKM2 proteins interaction in the HEK-293T cells co-transfected with Flag-tagged PKM2 and HA-tagged TIPE. <bold>D, E.</bold> IP and western blot analysis of the endogenous TIPE/PKM2 proteins interaction in the A375 cells. <bold>F.</bold> GST-pull down assay analysis of TIPE/PKM2 proteins interaction using purified GST-tagged PKM2 and TIPE-HA. <bold>G.</bold> TIPE (rabbit source, TIPE<sub>R</sub>) endogenously interacted with PKM2(mouse source, PKM2<sub>M</sub>) in G361 cells by using the Doulink assay. The results suggested that TIPE interacted with PKM2 to form a red color complex. The red color signal is generated only when the two proteins are too close to interaction. <bold>H, I.</bold> IP and western blot analysis of HA-tagged TIPE and Flag-tagged PKM2 fragment protein interaction in HEK-293T cells. <bold>J.</bold> IP and western blot analysis of the Flag-tagged PKM2 and HA-tagged TIPE fragment protein interaction in HEK-293T cells. <bold>K.</bold> Interfering TIPE decreased PKM2 dimeric formation but increased tetramer formation, as analyzed by BN-PAGE with β-actin as a loading control. <bold>L.</bold> Overexpression of TIPE increased PKM2 dimeric formation and decreased tetramer formation. <bold>M.</bold> Western blot showed that TIPE promoted PKM2 translocation into the nucleus. <bold>N.</bold> TIPE enhanced PKM2 translocation into the nucleus, and this phenomenon was diminished by the administration of TEPP-46 (100μM). *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01.</p></caption>
<graphic xlink:href="567124v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Since TIPE interacts with PKM2 in melanoma, we determined whether TIPE increases aerobic glycolysis by affecting PKM2 expression or its activity. The results showed that TIPE did not influence the expression of PKM2 at either the mRNA or the protein level (<bold>Fig. S5</bold>). Intriguingly, we demonstrated that dimeric PKM2 was reduced in TIPE-silenced A375 cells (<bold><xref rid="fig2" ref-type="fig">Fig. 2K</xref></bold>) and was increased following TIPE overexpression in G361 cells (<bold><xref rid="fig2" ref-type="fig">Fig. 2L</xref></bold>). Normally, a dimeric form of PKM2 with low affinity for its substrate, phosphoenolpyruvate (PEP), and a tetrameric form have a high PEP affinity. Moreover, the dimeric form of PKM2 is more prone to translocation into the nucleus and thus exerts protein kinase activity, which confers the Warburg effect and tumorigenesis(<xref ref-type="bibr" rid="c42">Zhou et al., 2022</xref>). Western blot analysis of nuclear and cytosolic fractions from A375 cells revealed that PKM2 primarily resided in the cytoplasm in which TIPE was downregulated. Likewise, the nuclear level of PKM2 was increased after overexpression of TIPE in G361 cells (<bold><xref rid="fig2" ref-type="fig">Fig. 2M</xref></bold>). Furthermore, we examined the distribution of PKM2 after TIPE overexpression by using a Thermo Fisher EVOS microscopic analysis. As shown in <bold><xref rid="fig2" ref-type="fig">Fig.2N</xref></bold>, PKM2 was predominantly present in the nucleus after TIPE overexpression, and this phenomenon was diminished by the administration of a PKM2 dimer formation suppressor (TEPP-46, 100μM). It has been shown that dimeric PKM2 promotes tumor progression by regulating the Warburg effect(<xref ref-type="bibr" rid="c42">Zhou et al., 2022</xref>). Thus, we speculated that TIPE restores the nuclear levels of PKM2 to promote melanoma tumorigenicity via a dimeric PKM2-dependent Warburg effect. <bold>TIPE requires PKM2 for transcriptional activation of HIF-1α</bold> Accumulating evidence has revealed that tetrameric PKM2 is enzymatically active towards pyruvate and acts as a transcriptional coactivator, while it dissociates into a dimer(<xref ref-type="bibr" rid="c35">Wei et al., 2020</xref>). Consequently, the dimeric form of PKM2 becomes a coactivator of HIF-1α to transcriptionally activate glycolytic genes in favor of the Warburg effect (<bold><xref rid="fig3" ref-type="fig">Fig.3A</xref></bold>)(<xref ref-type="bibr" rid="c29">Ouyang et al., 2018</xref>). As PKM2 and HIF-1α both play important roles in the metabolic reprogramming process, it is reasonable to believe that the interactions between TIPE and these two molecules could affect the glycolysis in melanoma. Thus, we investigated whether TIPE promoted the transcriptional activation of HIF-1α in a PKM2-dependent manner.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>TIPE promotes HIF-1α transcription in a PKM2-dependent manner.</title>
<p><bold>A.</bold> Proposed molecular mechanism by which dimeric PKM2 regulates cell proliferation and glycolysis by modulating HIF-1α activity. <bold>B.</bold> TIPE, especially when combined with PKM2, boosts relative HRE luciferase activity, as examined by luciferase reporter assay. <bold>C.</bold> TIPE promoted HRE activity in a dose- and PKM2-dependent manner. <bold>D, E.</bold> TIPE increases HIF-1α targeted genes, including <italic>LDHA</italic> and <italic>GLUT1</italic>, in a dose- and PKM2-dependent manner. <bold>F, G.</bold> TIPE promoted endogenous interaction between PKM2 and HIF-1α in melanoma cells using a Doulink assay. Interference of TIPE in A375 cells promoted the interaction between PKM2 and HIF-1α(upper) compared to that overexpression of TIPE in G361 cells decreased their interaction (lower). The density of the red color signaling means the interactive strength between PKM2 and HIF-1α affected by TIPE. <bold>H.</bold> TIPE enhanced the PKM2/HIF1a interaction in the nucleus. <bold>I.</bold> TIPE increased the exogenous interaction between PKM2 and HIF-1α in a dose-dependent manner in HEK-293T cells. <bold>J.</bold> TCGA dataset revealed that TIPE has a positive relationship with hypoxia score in melanoma. <bold>K.</bold> Higher expression of TIPE is associated with a relatively higher hypoxia score in melanoma. *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01; ***<italic>P</italic>&lt;0.001.</p></caption>
<graphic xlink:href="567124v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To confirm the effect of TIPE activation on HIF-1α transcriptional activity, we tested the ability of TIPE to activate the HRE reporter activity in HRE-luciferase plasmid transfected HEK-293T cells. Not surprisingly, significant augmentation of HRE promoter activation by TIPE was observed, especially when combined with PKM2 (<bold><xref rid="fig3" ref-type="fig">Fig.3B</xref></bold>). Consequently, TIPE activated HRE reporter activity in a dose-dependent manner, and this phenomenon was reversed after PKM2 knockdown, demonstrating that TIPE has critical effects on the activation of HIF-1α transcription in a PKM2-dependent manner (<bold><xref rid="fig3" ref-type="fig">Fig.3C</xref></bold>). HIF-1α targeted genes such as <italic>LDHA</italic> and <italic>GLUT1</italic> were also upregulated by TIPE in a dose-dependent manner and were reversed by interfering with PKM2 (<bold><xref rid="fig3" ref-type="fig">Fig.3D, E</xref></bold>). Due to PKM2 cooperated with HIF-1α to activate glycolytic genes during the Warburg effect, we used the Duolink method to confirm whether TIPE affects the endogenous interaction between HIF-1α and PKM2. The results showed that the interaction between HIF-1α and PKM2 was decreased by TIPE interference, whereas the interaction was increased when TIPE was overexpressed (<bold><xref rid="fig3" ref-type="fig">Fig.3F, G</xref></bold>). More interestingly, TIPE enhanced the PKM2/HIF-1α interaction in the nucleus, further indicating that TIPE induced PKM2 nuclear translocation and thus promoted its interaction with HIF-1α (<bold><xref rid="fig3" ref-type="fig">Fig.3H</xref></bold>). In addition, the Co-IP assay revealed that TIPE elevated this interaction in a dose-dependent manner (<bold><xref rid="fig3" ref-type="fig">Fig.3I</xref></bold>).</p>
<p>Moreover, we analyzed the correlation between TIPE and hypoxia scores using TCGA dataset. Interestingly, we found that the hypoxia score was significantly related to the expression of TIPE (<bold><xref rid="fig3" ref-type="fig">Fig.3J</xref></bold>) (<bold>Table S2</bold>), and the TIPE higher expression group had a higher hypoxia score than the lower expression group in melanoma (<bold><xref rid="fig3" ref-type="fig">Fig.3K</xref></bold>).</p>
<p>Collectively, these results demonstrated that TIPE has critical effects on the transcriptional activation of HIF-1α in a PKM2-dependent manner. <bold>TIPE promotes HIF-1α transcriptional activation via PKM2 Ser37 phosphorylation</bold> The presence of PKM2 in the nucleus enhances glucose metabolism by regulating HIF-1α(<xref ref-type="bibr" rid="c21">Luo et al., 2011</xref>). Our results preliminarily demonstrate that TIPE promotes PKM2 dimerization and nuclear import, thereby increasing HIF-1α transcriptional activation and promoting aerobic glycolysis. Normally, Erk1/2-dependent phosphorylation of PKM2 at serine 37 (Ser37) and FGFR1-dependent phosphorylation of PKM2 at tyrosine 105 (Tyr105)(<xref ref-type="bibr" rid="c17">Li et al., 2016</xref>; <xref ref-type="bibr" rid="c43">Zhou et al., 2018</xref>) are indicative of its dimerization and translocation, further promoting the Warburg effect and serving as a transcription factor coactivator(<xref ref-type="bibr" rid="c28">Novoyatleva et al., 2019</xref>; <xref ref-type="bibr" rid="c35">Wei et al., 2020</xref>). As shown in <bold><xref rid="fig4" ref-type="fig">Fig.4A</xref></bold>, interference with TIPE in A375 cells blocked PKM2 Ser37 phosphorylation, and overexpression of TIPE in G361 cells caused Ser37 phosphorylation compared to controls. However, the phosphorylation of PKM2 Tyr105 did not show any obvious changes. Consequently, we hypothesized that this transformation caused by Ser37 phosphorylation affects the interaction between TIPE and PKM2. As expected, the mutation of PKM2 at S37A blocked its interaction with TIPE, but not with the Y105D mutation (<bold><xref rid="fig4" ref-type="fig">Fig.4B</xref></bold>). Interestingly, this mutation also interfered with the interaction between PKM2 and HIF-1α, which was elevated by TIPE overexpression (<bold><xref rid="fig4" ref-type="fig">Fig.4C</xref></bold>). A previous study has revealed that TIPE promotes chemoresistance in acute myeloid leukemia (AML) by activating the ERK signaling pathway(<xref ref-type="bibr" rid="c31">Pang et al., 2020</xref>). In addition, phosphorylation of PKM2 at serine 37 is ERK1/2-dependent manner(<xref ref-type="bibr" rid="c38">Yang et al., 2012</xref>). TIPE does not serve as a phosphorylase to perform such post-translational modifications directly. Taken together, these results indicate that TIPE promotes PKM2 dimerization depending on ERK signaling. As expected, the ERK inhibitor, U0126, inhibited PKM2 Ser37 phosphorylation induced by TIPE overexpression (<bold><xref rid="fig4" ref-type="fig">Fig.4D</xref></bold>). To investigate whether TIPE affects the binding affinity of PKM2 to the Hif-1α specific binding site of the <italic>LDHA</italic> and <italic>GLUT1</italic> promoter using chromatin immunoprecipitation <italic>q</italic>PCR (ChIP-<italic>q</italic>PCR) analysis, we found that TIPE increased the binding of PKM2 to the <italic>LDHA</italic> and <italic>GLUT1</italic> promoters. This phenomenon, caused by the overexpression of TIPE, was diminished after the administration of TEPP-46, indicating that TIPE promoted the binding of PKM2 to the <italic>LDHA</italic> and <italic>GLUT1</italic> promoters in a dimeric PKM2-dependent manner (<bold><xref rid="fig4" ref-type="fig">Fig.4E, F</xref></bold>). Finally, we demonstrated that the augmentation of TIPE on HRE promoter activation or HIF-1α targeted genes such as <italic>LDHA</italic> and <italic>GLUT1</italic> was blocked by the S37A mutation (<bold><xref rid="fig4" ref-type="fig">Fig.4G-I</xref></bold>).</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>TIPE increases HIF-1α activity depending on PKM2 Ser37 phosphorylation.</title>
<p><bold>A.</bold> TIPE enhanced PKM2 Ser37 phosphorylation, but not that of Tyr105. <bold>B.</bold> PKM2 Ser37, but not Tyr105, increased its interaction with TIPE. <bold>C.</bold> PKM2 Ser37 mutation(S37A) hampered its interaction with HIF-1α promoted by TIPE. <bold>D.</bold> TIPE elevated PKM2 Ser37 phosphorylation in an ERK-dependent manner. <bold>E, F.</bold> TIPE enhanced PKM2 binding to the HRE for <italic>LDHA</italic> and <italic>GLUT1</italic> in a dimeric form dependent manner. <bold>G.</bold> PKM2 Ser37 mutation(S37A) inhibited the HRE activity induced by TIPE. <bold>H, I.</bold> PKM2 Ser37 mutation(S37A) decreased the expression of <italic>LDHA</italic> and <italic>GLUT1</italic> that promoted by TIPE. **<italic>P</italic>&lt;0.01; ***<italic>P</italic>&lt;0.001.</p></caption>
<graphic xlink:href="567124v1_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>In brief, we revealed that TIPE promoted HIF-1α transcriptional activation via ERK-dependent PKM2 Ser37 phosphorylation.</p>
</sec>
<sec id="s2c">
<title>TIPE facilitates melanoma tumorigenesis and aerobic glycolysis in a dimeric PKM2-dependent manner</title>
<p>Several studies have demonstrated that dimeric PKM2 increases tumor progression by regulating the Warburg effect. Therefore, we speculated that TIPE promotes melanoma growth through a dimeric PKM2-dependent Warburg effect. To demonstrate this, we knocked down TIPE in A375 cells and found that cell proliferation was decreased. Interestingly, we found that Pyridoxine, a PKM2 dimer formation inducer (<xref ref-type="bibr" rid="c35">Wei et al., 2020</xref>), was sufficient to abrogate the TIPE silencing-mediated cell proliferation (<bold><xref rid="fig5" ref-type="fig">Fig.5A</xref></bold>). Consistently, TEPP-46, a PKM2 dimer formation suppressor, was sufficient to reverse the increased proliferative capacity induced by TIPE-overexpression in G361 cells (<bold><xref rid="fig5" ref-type="fig">Fig.5B</xref></bold>). Clone formation ability (<bold><xref rid="fig5" ref-type="fig">Fig.5C, D</xref></bold>) and <italic>in vivo</italic> experiments (<bold><xref rid="fig5" ref-type="fig">Fig.5E-G</xref></bold>) also demonstrated this phenomenon. Interestingly, we found that decreased ECAR, glycolysis, and glycolytic capacity induced by TIPE interference could be fully antagonized by Pyridoxine in A375 cells (<bold><xref rid="fig5" ref-type="fig">Fig.5H</xref>-J</bold>). In addition, TEPP-46 reversed the ECAR, glycolysis, and glycolytic capacity induced by TIPE overexpression in G361 cells (<bold><xref rid="fig5" ref-type="fig">Fig.5K</xref>-M</bold>).</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>TIPE promotes melanoma cells proliferation and glycolysis depending on PKM2 dimerization.</title>
<p><bold>A.</bold> Pyridoxine (which facilitates PKM2 dimerization) treatment reversed the inhibition of cell proliferation that induced via interfering TIPE. <bold>B.</bold> Administration of TEPP-46 rescued TIPE overexpression induced cell proliferation. <bold>C, D.</bold> TIPE promoted melanoma clone formation in a dimeric PKM2-dependent manner. <bold>E-G.</bold> <italic>In vivo</italic> experiments showed that TIPE promoted melanoma proliferation via the dimerization of PKM2. <bold>H-J.</bold> Activation of PKM2 dimerization reversed the inhibition of glycolysis and glycolytic capacity after TIPE interfering. In contrast, inhibition of PKM2 dimerization altered this phenomenon (<bold>K-M</bold>)<bold>. N.</bold> Pyridoxine increased the cell proliferation that was inhibited by TIPE-sh. It was rescued by inhibition of HIF-1α. <bold>O.</bold> TEPP-46 inhibited the TIPE-induced cell proliferation, and was rescued by overexpression of HIF-1α. <bold>P.</bold> Pyridoxine enhanced the Warberg effect that was suppressed by TIPE-sh, and it was diminished via administration of PX-478(a HIF-1α inhibitor). <bold>Q.</bold> TEPP-46 can suppression of the Warberg effect that was increased by overexpression of TIPE, this phenomenon was diminished by overexpression of HIF-1α. *<italic>P</italic>&lt;0.05; ***<italic>P</italic>&lt;0.001.</p></caption>
<graphic xlink:href="567124v1_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Lastly, to further demonstrate how TIPE affects the PKM2/HIF-1α pathway during the Warburg effect, we revealed that inhibition of PKM2 dimerization can rescue TIPE-induced cell proliferation. However, this phenomenon was diminished by the activation of HIF-1α, demonstrating that TIPE promotes melanoma cell proliferation via dimeric PKM2 dependent HIF-1α activation (<bold><xref rid="fig5" ref-type="fig">Fig.5N, O</xref></bold>). More interestingly, we evidenced that suppression of PKM2 dimerization inhibited the TIPE-mediated Warburg effect. In addition, this phenomenon was diminished by the activation of HIF-1α (<bold><xref rid="fig5" ref-type="fig">Fig.5P, Q</xref></bold>).</p>
<p>Taken together, these data suggest that TIPE regulates cell growth and the Warburg effect by inducing the formation of dimeric PKM2, and thus activating the HIF-1α pathway.</p>
</sec>
<sec id="s2d">
<title>TIPE accelerates melanoma cells stem-like phenomenon via promoting PKM2 dimerization under normoxic conditions</title>
<p>Increasing evidence has shown that the HIF-1α pathway is associated with acquisition of cancer stem-like properties(<xref ref-type="bibr" rid="c36">Weinstein et al., 2022</xref>; <xref ref-type="bibr" rid="c44">Zhu et al., 2022</xref>). To confirm the effects of TIPE on the stemness of melanoma cells under normoxic conditions, we examined the stemness-associated features <italic>in vitro</italic>. First, we measured cancer stem-like phenotype markers, including <italic>NANOG</italic>, <italic>NOTCH</italic>, <italic>OCT3/4</italic>, <italic>SOX2</italic> and <italic>BMI-1</italic>. The results showed that the markers were increased after overexpression of TIPE in G361 cells (<bold><xref rid="fig6" ref-type="fig">Fig.6A</xref></bold>) and were reduced after TIPE interference in A375 cells by using <italic>q</italic>PCR method (<bold><xref rid="fig6" ref-type="fig">Fig.6B</xref></bold>). We further revealed that TIPE increased the migration ability and increased sphere formation (<bold><xref rid="fig6" ref-type="fig">Fig.6C, D</xref></bold>). In addition, TIPE significantly increased the chemosensitivity of melanoma cell to sorafenib (<bold><xref rid="fig6" ref-type="fig">Fig.6E, F</xref></bold>). Next, we examined the tumorigenicity of melanoma cells with TIPE knockdown <italic>in vivo</italic> by injecting Ctrl-sh or TIPE-sh A375 cells subcutaneously into nude mice at three dilutions (1×10<sup>6</sup>, 1×10<sup>5</sup> and 1×10<sup>4</sup>) and allowing them to grow for four weeks. The Confidence intervals (CIs) for 1/ (stem cell frequency) using extreme limiting dilution were calculated as previous reported(<xref ref-type="bibr" rid="c14">Hu and Smyth, 2009</xref>; <xref ref-type="bibr" rid="c27">Niu et al., 2021</xref>). The estimated CI for the frequency of CSCs in the TIPE knockdown group was 202749, compared with 18441 in the control group (<italic>P</italic>&lt;0.001) (<bold><xref rid="fig6" ref-type="fig">Fig.6G</xref></bold>) (<bold>Table S3, 4</bold>). Moreover, CD44<sup>+</sup> subpopulations were significantly elevated, as detected using a fluorescence-activated cell sorting (FACS) assay (<bold><xref rid="fig6" ref-type="fig">Fig.6H, I</xref></bold>).</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title>TIPE fostered PKM2 dimerization increases melanoma stem-like phenomenon.</title>
<p><bold>A, B.</bold> TIPE increased the cancer stem-like phenotype markers, including <italic>NANOG</italic>, <italic>NOTCH</italic>, <italic>OCT3/4</italic>, <italic>SOX2</italic> and <italic>BMI-1</italic>, measured by <italic>q</italic>PCR. <bold>C-F.</bold> The effects of TIPE on the stemness of melanoma cells are shown by <italic>in vitro</italic> cell migration (<bold>C</bold>), sphere formation (<bold>D</bold>), and chemoresistance (<bold>E, F</bold>). <bold>G.</bold> Limiting dilution xenograft formation of A375 cells with TIPE interference. <bold>H, I.</bold> TIPE increased the expression of CD44<sup>+</sup> cells in melanoma. <bold>J, K.</bold> The effects of TIPE on the stemness of melanoma cells following the administration of TEPP-46, and this phenomenon was reversed by overexpression of HIF-1α, as evidenced by sphere formation (<bold>J</bold>) and CD44<sup>+</sup> cell population (<bold>K</bold>). *<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01; ***<italic>P</italic>&lt;0.001.</p></caption>
<graphic xlink:href="567124v1_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Because TIPE promotes HIF-1α transcriptional activation in a dimeric PKM2-dependent manner, we performed a sphere formation assay by overexpressing TIPE in G361 cells. The results showed that TEPP-46 partially reversed mammosphere formation induced by TIPE overexpression. Moreover, overexpression of HIF-1α diminished this phenomenon, indicating that TIPE-induced sphere formation depended on dimeric PKM2-dependent HIF-1α activation (<bold><xref rid="fig6" ref-type="fig">Fig.6J</xref></bold>). In addition, the increased CD44<sup>+</sup> subpopulations of G361 cells induced by TIPE were decreased by the administration of TEPP-46, and could be rescued by overexpression of HIF-1α(<bold><xref rid="fig6" ref-type="fig">Fig.6K</xref></bold>).</p>
<p>These findings strongly suggest that TIPE maintains melanoma cell stemness via dimeric PKM2-dependent HIF-1α activation.</p>
</sec>
<sec id="s2e">
<title>TIPE is positively correlated with the levels of PKM2 Ser37 phosphorylation and cancer stem cell markers</title>
<p>We analyzed the expression of TIPE in melanoma and benign skin tumors, and the results showed that the expression of TIPE was dramatically increased compared to controls using a tissue chip (<bold><xref rid="fig7" ref-type="fig">Fig.7A, B</xref></bold>). To determine if there was a correlation between TIPE and PKM2 Ser37 levels, TIPE and PKM2 Ser37 expression was analyzed by IHC staining. The results showed that TIPE expression was positively correlated with PKM2 Ser37 expression (<italic>P</italic> &lt; 0.001) (<bold><xref rid="fig7" ref-type="fig">Fig.7C, D</xref></bold>).</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7.</label>
<caption><title>TIPE positively corelated with cancer stem cell markers and the levels of p-PKM2(Ser37).</title>
<p><bold>A, B.</bold> Higher expression of TIPE was observed in melanoma tumor tissues than in the control, as evidenced by immunohistochemistry. <bold>C, D.</bold> The expression of TIPE correlated well with p-PKM2(Ser37) in melanoma tumor tissues. <bold>E.</bold> Similarly, a good correlation was observed between TIPE, p-PKM2(Ser37), LDH, and CD44 in mouse xenografts. <bold>F-I.</bold> In addition, the expression of TIPE was positively correlated with CSCs markers, including <italic>BMI1</italic>, <italic>NANOG</italic>, <italic>NOTCH1</italic>, and <italic>OCT3/4</italic>(<italic>POU5F1</italic>) in TCGA dataset. <bold>J.</bold> A brief model depicting the functional impact of TIPE on metabolic reprogramming in melanoma. ***<italic>P</italic>&lt;0.001.</p></caption>
<graphic xlink:href="567124v1_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Consistent with the above findings, immunohistochemistry (IHC) results showed that TIPE, PKM2 Ser37, LDH, and CSCs marker CD44 were inhibited in A375 TIPE-interfering cell-derived xenografts (<bold><xref rid="fig7" ref-type="fig">Fig.7E</xref></bold>). Lastly, TCGA dataset revealed that TIPE has a positive relationship with CSCs markers including <italic>BMI1</italic>, <italic>NANOG</italic>, <italic>NOTCH1</italic>, and <italic>OCT3/4</italic>(<italic>POU5F1</italic>) in melanoma (<bold><xref rid="fig7" ref-type="fig">Fig.7F</xref>-I</bold>).</p>
<p>These results further demonstrate that TIPE maintains cancer stem cell phenotypes in a PKM2 dimerization manner.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Accumulating evidence has revealed that TIPE serves as an oncogene and a negative regulator of apoptosis. Its overexpression is positively associated with the development of various cancers, including liver, lung, and breast cancers(<xref ref-type="bibr" rid="c20">Lou et al., 2022</xref>; <xref ref-type="bibr" rid="c24">Niture et al., 2018</xref>). However, Chen et al. reported that TIPE initially inhibits cancer cell proliferation but promotes tumor migration and metastasis(<xref ref-type="bibr" rid="c16">Li et al., 2021</xref>). In addition, a previous report has demonstrated that TIPE functions as a tumor suppressor in certain inflammatory carcinogenesis(<xref ref-type="bibr" rid="c20">Lou et al., 2022</xref>). These results suggest that TIPE plays a variety of roles in cancer progression. Interestingly, Niture et al. reported that TIPE promotes prostate cancer progression by regulating oxidative phosphorylation and glycolysis(<xref ref-type="bibr" rid="c25">Niture et al., 2021</xref>). However, the mechanism through which TIPE regulates metabolic reprogramming remains unclear. Here, we demonstrate that TIPE facilitates the Warberg effect by promoting dimeric PKM2-mediated HIF-1α transactivation in melanoma. Therefore, targeting TIPE may offer a novel therapeutic approach for melanoma treatment.</p>
<p>Mammalian pyruvate kinase consists of four isoforms, M1, M2, L, and R, which are encoded by two distinct genes (PKM and PKLR) (<xref ref-type="bibr" rid="c33">Valentini et al., 2002</xref>). Although these isoforms share similar features, only PKM2 exhibits the lowest basal enzymatic activity and is capable of configuration transformation between the tetramer and dimer, meeting differential metabolic demands(<xref ref-type="bibr" rid="c23">Morgan et al., 2013</xref>; <xref ref-type="bibr" rid="c32">Puckett et al., 2021</xref>). Cancer cells shift towards the preferential expression of the specific isoform of PKM2, especially its dimeric form, and serve as a pivotal metabolic enzyme that promotes the activation of oncogenic pathways in tumors(<xref ref-type="bibr" rid="c15">Icard et al., 2022</xref>). Normally, PKM2 enzymatic activity is accurately modulated in a variety of ways, such as post-translational modifications or metabolite binding, to maintain balanced levels in tumor cells(<xref ref-type="bibr" rid="c32">Puckett et al., 2021</xref>). Here, we showed that TIPE promoted melanoma tumorigenesis by promoting glycolysis. The results showed that TIPE interacts with PKM2 and may participate in glycolysis. However, TIPE did not influence the expression of PKM2 at either the mRNA or the protein level. Because of the modulation of PKM2 kinetic properties primarily via its dimer and tetramer configurations, we demonstrated that TIPE could promote its dimeric form transformation, increasing PKM2 residing in the nucleus. However, the downstream signaling pathways that are mediated by TIPE in melanoma remain largely unknown.</p>
<p>The nuclear PKM2 routinely serves as a coactivator to transcriptionally activate certain metabolic genes(<xref ref-type="bibr" rid="c6">Cluntun et al., 2017</xref>; <xref ref-type="bibr" rid="c40">Zhang et al., 2019</xref>). Because TIPE binds PKM2 and transports it into the nucleus, the dimeric form of PKM2 more easily enters the nucleus to become a coactivator of HIF-1α, resulting in the upregulation of HIF-1α targeted genes such as <italic>LDHA</italic> and, <italic>GLUT1</italic>. Thus, we elucidate these relationships in the next step. To verify whether TIPE activates HIF-1α transcriptional activity, we found that TIPE significantly increased the activation of the HRE promoter, especially when combined with PKM2. However, this activation was diminished by interfering with PKM2, indicating that TIPE has critical effects on the activation of HIF-1α transcription in a PKM2-dependent manner. Because PKM2 interacts with HIF-1α and potentiates PKM2-mediated HIF-1α transcription, we found that TIPE increased the interaction between HIF-1α and PKM2. In TCGA dataset, the hypoxia score was positively correlated with the mRNA expression of TIPE in melanoma, and the TIPE higher expression group had a higher hypoxia score than the lower expression group.</p>
<p>The mechanisms associated with PKM2 translocation are diverse, the most important of which is Erk1/2-dependent phosphorylation of PKM2 at serine 37 (Ser37) and FGFR1-dependent phosphorylation of PKM2 at tyrosine 105 (Tyr105)(<xref ref-type="bibr" rid="c17">Li et al., 2016</xref>; <xref ref-type="bibr" rid="c43">Zhou et al., 2018</xref>). Consequently, we demonstrated that TIPE increased the levels of PKM2 Ser37 but not PKM2 Tyr105. Furthermore, we conjectured that this transformation caused by Ser37 phosphorylation affects the interaction between TIPE and PKM2. The results showed that mutation of PKM2 at S37A blocked its interaction with TIPE but not with Y105D. Because phosphorylation of PKM2 at serine 37 is dependent on ERK1/2(<xref ref-type="bibr" rid="c38">Yang et al., 2012</xref>) and TIPE promotes AML chemoresistance by activating the ERK signaling pathway(<xref ref-type="bibr" rid="c31">Pang et al., 2020</xref>), we used an ERK inhibitor to further demonstrate the activation of HIF-1αinduced by TIPE. Not surprisingly, we found that TIPE facilitates the Warberg effect predominantly by driving PKM2 Ser37 phosphorylation. Furthermore, we demonstrated that the augmentation of TIPE on HRE promoter activation or HIF-1α targeted genes such as <italic>LDHA</italic> and <italic>GLUT1</italic> was blocked by the S37A mutation, as previously reported. These results demonstrated that TIPE promotes HIF-1α transcriptional activation via ERK-dependent PKM2 Ser37 phosphorylation.</p>
<p>Increasing evidence has shown that HIF-1α promotes tumor progression, metastasis, and therapeutic drug resistance by maintaining cancer stemness(<xref ref-type="bibr" rid="c7">Cui et al., 2017</xref>; <xref ref-type="bibr" rid="c27">Niu et al., 2021</xref>). Here, we observed that TIPE significantly enhanced tumorigenesis, glycolysis, and CSC properties under normoxia in melanoma, whereas suppression of PKM2 dimerization rescued these TIPE-induced effects. Interestingly, we revealed that decreasing of PKM2 dimerization can rescue TIPE induced cell proliferation, glycolysis, and CSC properties. However, this phenomenon was diminished by activation of HIF-1α, demonstrating that TIPE promotes melanoma cells proliferation, glycolysis, and CSC properties via dimeric PKM2 dependent HIF-1α activation. Furthermore, using a tissue ship, we showed that the expression of TIPE in melanoma tissues was dramatically increased compared to that in benign skin tumor tissues. To determine if there was a correlation between TIPE and PKM2 Ser37 levels, the results also demonstrated that TIPE expression was positively correlated with PKM2 Ser37 levels. Consistently, the expression of TIPE has a positive relationship with PKM2 Ser37, LDH, and the CSCs marker CD44 in TIPE-overexpressing cell-derived xenografts. TCGA dataset revealed that TIPE has a positive relationship with CSCs markers, including BMI1, NANOG, NOTCH1, and OCT3/4(POU5F1) in melanoma. These results further demonstrate that TIPE maintains melanoma cell stem phenotypes in a PKM2 dimerization manner.</p>
<p>In summary, we identified that TIPE serves as an oncogenic candidate for melanoma and determined that TIPE promotes the Warburg effect and maintains the stemness of melanoma. TIPE binds to PKM2, inducing its dimeric transformation by enhancing ERK-dependent PKM2 Ser37 phosphorylation, and thus activating the transcription of HIF-1α, providing tumorigenicity and cancer stem-like phenomena for melanoma progression. The newly identified TIPE/PKM2/HIF-1α axis is an ideal therapeutic target for melanoma and opens an avenue for the development of a novel strategy for precision therapy.</p>
</sec>
<sec id="s4">
<title>Materials and methods</title>
<sec id="s4a">
<title>Cell culture and plasmids construction</title>
<p>Human A375, A875, G361, MM96L and HEK-293T cell lines were purchased from the Shanghai Institute of Cell Biology (Chinese Academy of Sciences, Shanghai, China) and were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) at 37°C under 5% CO<sub>2</sub>. The TIPE overexpression lentiviral vector (TIPE), TIPE expression knockdown vector (TIPE-sh) and their control vectors were constructed by GeneChem company (Shanghai, China). HIF-1α, PKM2-Flag, TIPE-HA and their truncated vectors were constructed in our laboratory. The mutant vectors such as PKM2 S37A were synthesized by Tsingke Biology Co., Ltd.(Beijing, China). All plasmids were transfected into the cells according to the manufacturer’s protocol.</p>
</sec>
<sec id="s4b">
<title>Cell proliferation, cell cycle and colony formation assays</title>
<p>Cell proliferation was measured using the Cell Counting Kit-8 method (Dojindo, Shanghai, China). For the cell cycle assay, the cells were stained with propidium iodide (PI; Sigma, USA) and were measured with a flow cytometer (FACS Aria 2, BD, USA). For the colony formation assay, cells were seeded, fixed and stained as previously described(<xref ref-type="bibr" rid="c37">Yang et al., 2022</xref>).</p>
</sec>
<sec id="s4c">
<title>Transwell assay</title>
<p>Tranwell assay was performed as we previous described(<xref ref-type="bibr" rid="c37">Yang et al., 2022</xref>). Photographs of at least three randomly selected fields were captured and were counted.</p>
</sec>
<sec id="s4d">
<title>Bioinformatics, transcriptomics and metabolomics analyses</title>
<p>The correlations between TIPE and HIF1A, Hypoxia score, cancer stem cells (CSCs) markers including <italic>BMI1</italic>, <italic>NANOG</italic>, <italic>NOTCH1</italic> and <italic>OCT3/4</italic>(<italic>POU5F1</italic>) were estimated by using the ASSISTANT for Clinical Bioinformation website (<ext-link ext-link-type="uri" xlink:href="https://www.aclbi.com/static/index.html">https://www.aclbi.com/static/index.html</ext-link>#/). Transcriptomics and metabolomics were performed and analyzed by GeneChem company (Shanghai, China). Overexpression of TIPE into G361 cells, interfering TIPE in A375 cells and their control group were randomly divided into three groups to perform transcriptomic analyses, respectively. Interfering TIPE in A375 cells and its control group were randomly divided into six groups to perform metabolomic analyses.</p>
</sec>
<sec id="s4e">
<title>ATP content, ATPase activity, pyruvate kinase activity and lactic acid content measurement</title>
<p>The concentration of ATP was determined 72h after overexpression or interfering of TIPE by using an ATP assay kit (Beyotime, S0026) according to the manufacturer’s instructions. ATPase activity was measured by using an ATPase Assay Kit (Sigma-Aldrich, MAK113). Pyruvate kinase activity and lactate production after overexpression or interfering of TIPE were measured using a Pyruvate Kinase Activity Assay Kit (Nanjing Jiancheng, A076-1-1) and Lactic Acid Assay Kit (Nanjing Jiancheng, A019-2-1) according to the manufacturer’s instruction, respectively.</p>
</sec>
<sec id="s4f">
<title>ECAR</title>
<p>The Extra Cellular Acidification Rate (ECAR) of melanoma cells were determined using the Seahorse XF extracellular flux analyzer (Agilent, Santa Clara, CA, USA). The cells were plated, washed before analysis. The cells were then treated at specific time points: glucose (10 mM), followed by oligomycin (1 μM) and 2-DG (50 mM). Finally, the ECAR were measured by the Seahorse XF software.</p>
</sec>
<sec id="s4g">
<title>Chromatin Immunoprecipitation (ChIP) Quantitative PCR (ChIP-qPCR)</title>
<p>Melanoma cells were cross-linked with 1% formaldehyde, lysed with sodium dodecyl sulfate buffer and sonicated. Sheared DNA was immunoprecipitated with PKM2 antibody and negative control anti-IgG, and quantified using SYBR Green Realtime PCR analysis (ABI, USA). Primer sequences are listed in <bold>Table S5</bold>. Fold enrichment was calculated based on Ct as 2<sup>−Δ(ΔCt)</sup>, where ΔCt = Ct<sub>IP</sub> - Ct<sub>Input</sub> and Δ(ΔCt) = ΔCt<sub>antibody</sub> - ΔCt<sub>IgG</sub>.</p>
</sec>
<sec id="s4h">
<title>Sphere formation assay</title>
<p>Melanoma cells transfected with TIPE or TIPE-sh were plated onto 24-well low attachment surface polystyrene plates (Corning, USA). Cells were grown in DMEM/F12 medium (Invitrogen, USA) for approximately 10 days supplemented with 20ng/mL EGF (Bioworld, BK0026), 2% B27 (Invitrogen, 17504044), 20 ng/mL basic FGF (PeproThech, #100-18B), and 1% N2(Invitrogen, 17502048).</p>
</sec>
<sec id="s4i">
<title>Luciferase reporter assay</title>
<p>Human HEK-293T cells were seeded onto 48-well plates and transiently transfected with pHRE-Firefly luciferase reporter, TIPE-HA and PKM2-Flag or sh-RNA vector targeting PKM2 plasmids together with internal control reporter pTK (Thymidine kinase)-Renilla luciferase by Lipofectamine™ 2000 reagent (Thermo, USA). FLuc and RLuc activities were determined using the Dual-Luciferase Assay System (Promega, USA).</p>
</sec>
<sec id="s4j">
<title><italic>q</italic>PCR</title>
<p>mRNA was isolated and cDNAs were synthesized by using a Prime Script RT Reagent Kit (TaKaRa, China) according to manufacturer’s instruction. <italic>q</italic>PCR was performed using Real SYBR Mixture (CoWin Bioscience, China) on an ABI PRISM 7500 instrument (ThermoFisher, USA). The sequences of the primers used in this study are listed in <bold>Table S5</bold>.</p>
</sec>
<sec id="s4k">
<title>Duolink proximity ligation assay (PLA)</title>
<p>Duolink® In Situ PLA® kit (Sigma-Aldrich, DUO92101) was performed to demonstrate the endogenous interactions between TIPE and PKM2, and to interpret how TIPE impact the interactions between HIF-1α and PKM2 according to we described previously(<xref ref-type="bibr" rid="c37">Yang et al., 2022</xref>; <xref ref-type="bibr" rid="c41">Zhao et al., 2019</xref>). Quantification analysis was performed using the ImageJ software.</p>
</sec>
<sec id="s4l">
<title>Nuclear and cytosolic fractionation</title>
<p>Nuclear and cytosolic fractions were prepared using NE-PER Extraction Reagents (Thermo, 78833) according to the manufacturer’s recommendation. Finally, both cytosolic and nuclear subfractions were stored in -80°C prior to western blot.</p>
</sec>
<sec id="s4m">
<title>Western blot</title>
<p>The prepared lysates were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto PVDF membranes (Bio-Rad, USA). The membranes were then blocked and incubated overnight at 4°C with the primary antibodies (as listed in <bold>Table S6</bold>). After incubated with secondary antibodies, the protein bands were visualized using a Tanon 5200 Imager (Shanghai, China).</p>
</sec>
<sec id="s4n">
<title>Immunohistochemical and immunofluorescence</title>
<p>Melanoma tissue chip was purchased from Zhongke Guanghua (Xi’an, China) Intelligent Biotechnology Co., Ltd.(#K063Me01), and the clinicopathological characteristics of melanoma specimens are summarized in <bold>Table S7</bold>. Immunohistochemistry (IHC) staining was performed as previously reported. The samples were finally analyzed by using semiquantitative scoring criteria. The staining index values (0-12) were obtained and calculated(<xref ref-type="bibr" rid="c37">Yang et al., 2022</xref>). For immunofluorescence, cells were seeded onto 24-well plates at a density of 5,000 cells per well. Then, the cells were fixed using 4% formaldehyde solution and permeabilized with 0.5% Triton X-100 solution. Finally, cells were incubated overnight with antibodies prior to blocked with 1% bovine serum albumin (BSA) in phosphate-buffered saline containing 0.2% Tween-20. The fluorescence images of the cells were acquired with a fluorescence microscope equipped with appropriate filter combinations.</p>
</sec>
<sec id="s4o">
<title>Co-immunoprecipitation (Co-IP) and Co-immunoprecipitation mass spectrometry (Co-IP/MS)</title>
<p>For Co-IP, the cells were seeded, harvested, and were then washed twice with PBS and digested and lysed in lysis buffer. The lysed supernatant was incubated with Tag-conjugated beads to bait the potential interacted proteins according to the manufacturer’s instruction. For Co-IP/MS, the beads consequently were washed, eluted, resolved, and then stained with Coomassie brilliant blue. The bands were excised and digested with chymotrypsin and subjected to LC-MS/MS sequencing and data analysis by OBiO Technology Corp.,Ltd. (Shanghai, China).</p>
</sec>
<sec id="s4p">
<title>Flow Cytometry Analysis</title>
<p>Cell apoptosis was measured by using a Cell Apoptosis Analysis Kit (Engreen Biosystem Co, Ltd., Beijing, China). The cells were then incubated in serum-free medium for starvation prior to analysis and fixed using 70% ethanol for 12 h. Consequently, cells were washed, incubated with propidium iodide, and analyzed by a FACS scanner (Aria II, BD, USA). For CD44 analyzing, the cells were seeded, harvested, and incubated with anti-CD44 fluorescent antibody. Isotype-matched human immunoglobulins served as controls. Finally, the cells were counted with the FACS scanner.</p>
</sec>
<sec id="s4q">
<title>Mouse xenograft tumor study</title>
<p>Xenograft tumor studies were conducted utilizing the 6-week-old male BALB/c nude mice purchased from the Shanghai SLAC Laboratory Animal Co., Ltd.. The total number of mice was randomly divided into respective groups and maintained in a standard pathogen free environment. All the animal experiments were approved by the Animal Ethics Committee of Zibo Central Hospital, Binzhou Medical University. Tumor growth was monitored regularly and the length, width, and height measurements taken every 7 days. All mice were killed by 10 weeks post injection. For the rescue test, one week after injection, mice bearing TIPE-vector were treated with TEPP-46. TEPP-46 (50mg/kg) or vehicle control (0.9% NaCl) was administrated via intraperitoneal injection. At the end of experiment, mice were euthanized and tumors were collected. Tumors were fixed with 4% paraformaldehyde for further immunohistochemistry (IHC) analysis.</p>
</sec>
<sec id="s4r">
<title>Statistical analysis</title>
<p>GraphPad Prism (GraphPad Software, San Diego, CA) was used for statistical analyses. Two-tailed Student’s t-tests were used to compare two groups. Linear regression analysis was explored to analyze the correlation of TIPE with other indicators. All the data are shown as the mean with standard deviations (SD) from at least three independent experiments. A <italic>P</italic> value of &lt;0.05 was considered statistically significant for all tests.</p>
</sec>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability Statement</title>
<p>All the data needed to evaluate the conclusions of the study are presented in this paper. Additional data related to this study may be requested from the corresponding author.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by the National Natural Science Foundation of China (Nos. 81972002, 12304241, 81971491), Natural Science Foundation of Shandong Province (ZR2023QC68, ZR2023MC136, ZR2021MC083, ZR2021MC165), Medicine and Health Science Technology Development Projects of Shandong Province (202102050803 and 2018WS534), and Qingdao Postdoctoral Application Innovation Project (QDBSH20230102068).</p>
</ack>
<sec id="s6">
<title>Ethics approval</title>
<p>This study has been approved by the Medical Ethics Committee, the Animal Care and Use Committee of Zibo Central Hospital, Binzhou Medical University.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>Peiqing Zhao: Conceptualization, Supervision. Jianxin Du: Methodology, Writing-Original draft preparation. Maojin Tian: Data curation, Investigation. Le Yang: Investigation. Ziqian Zhao: Investigation. Jigang Li: Validation. Qingqing Yin: Software. Lianqing Wang: Data curation. Wei Hu: Investigation. Yunwei Lou: Visualization.</p>
</sec>
<sec id="s8">
<title>Declaration of competing interest</title>
<p>The authors declare that they have no conflicts of interest concerning this article.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Baik</surname>, <given-names>S.H.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Kang</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Choi</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Chung</surname></string-name>, <string-name><given-names>J.I.</given-names> <surname>Kim</surname></string-name>, and <string-name><given-names>I.</given-names> <surname>Mook-Jung</surname></string-name>. <year>2019</year>. <article-title>A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer’s Disease</article-title>. <source>Cell Metab</source>. <volume>30</volume>:<fpage>493</fpage>–<lpage>507 e496</lpage>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Brunner</surname>, <given-names>J.S.</given-names></string-name>, and <string-name><given-names>L.W.S.</given-names> <surname>Finley</surname></string-name>. <year>2022</year>. <article-title>Metabolic determinants of tumour initiation</article-title>. <source>Nat Rev Endocrinol</source>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>, <given-names>C.</given-names></string-name>, <string-name><given-names>W.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Han</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Mei</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Pan</surname></string-name>, and <string-name><given-names>S.</given-names> <surname>Zhu</surname></string-name>. <year>2022a</year>. <article-title>Vitamin B5 rewires Th17 cell metabolism via impeding PKM2 nuclear translocation</article-title>. <source>Cell Rep</source>. <volume>41</volume>:<fpage>111741</fpage>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Cattoglio</surname></string-name>, <string-name><given-names>G.M.</given-names> <surname>Dailey</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Tjian</surname></string-name>, and <string-name><given-names>X.</given-names> <surname>Darzacq</surname></string-name>. <year>2022b</year>. <article-title>Mechanisms governing target search and binding dynamics of hypoxia-inducible factors</article-title>. <source>Elife</source>. <volume>11</volume>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><string-name><surname>Christofk</surname>, <given-names>H.R.</given-names></string-name>, <string-name><given-names>M.G.</given-names> <surname>Vander Heiden</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>J.M.</given-names> <surname>Asara</surname></string-name>, and <string-name><given-names>L.C.</given-names> <surname>Cantley</surname></string-name>. <year>2008</year>. <article-title>Pyruvate kinase M2 is a phosphotyrosine-binding protein</article-title>. <source>Nature</source>. <volume>452</volume>:<fpage>181</fpage>–<lpage>186</lpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Cluntun</surname>, <given-names>A.A.</given-names></string-name>, <string-name><given-names>M.J.</given-names> <surname>Lukey</surname></string-name>, <string-name><given-names>R.A.</given-names> <surname>Cerione</surname></string-name>, and <string-name><given-names>J.W.</given-names> <surname>Locasale</surname></string-name>. <year>2017</year>. <article-title>Glutamine Metabolism in Cancer: Understanding the Heterogeneity</article-title>. <source>Trends Cancer</source>. <volume>3</volume>:<fpage>169</fpage>–<lpage>180</lpage>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><string-name><surname>Cui</surname>, <given-names>C.P.</given-names></string-name>, <string-name><given-names>C.C.</given-names> <surname>Wong</surname></string-name>, <string-name><given-names>A.K.</given-names> <surname>Kai</surname></string-name>, <string-name><given-names>D.W.</given-names> <surname>Ho</surname></string-name>, <string-name><given-names>E.Y.</given-names> <surname>Lau</surname></string-name>, <string-name><given-names>Y.M.</given-names> <surname>Tsui</surname></string-name>, <string-name><given-names>L.K.</given-names> <surname>Chan</surname></string-name>, <string-name><given-names>T.T.</given-names> <surname>Cheung</surname></string-name>, <string-name><given-names>K.S.</given-names> <surname>Chok</surname></string-name>, <string-name><given-names>A.C.Y.</given-names> <surname>Chan</surname></string-name>, <string-name><given-names>R.C.</given-names> <surname>Lo</surname></string-name>, <string-name><given-names>J.M.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>T.K.</given-names> <surname>Lee</surname></string-name>, and <string-name><given-names>I.O.L.</given-names> <surname>Ng</surname></string-name>. <year>2017</year>. <article-title>SENP1 promotes hypoxia-induced cancer stemness by HIF-1alpha deSUMOylation and SENP1/HIF-1alpha positive feedback loop</article-title>. <source>Gut</source>. <volume>66</volume>:<fpage>2149</fpage>–<lpage>2159</lpage>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><string-name><surname>D’Aguanno</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>F.</given-names> <surname>Mallone</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Marenco</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Del Bufalo</surname></string-name>, and <string-name><given-names>A.</given-names> <surname>Moramarco</surname></string-name>. <year>2021</year>. <article-title>Hypoxia-dependent drivers of melanoma progression</article-title>. <source>J Exp Clin Cancer Res</source>. <volume>40</volume>:<fpage>159</fpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><string-name><surname>Dhanesha</surname>, <given-names>N.</given-names></string-name>, <string-name><given-names>R.B.</given-names> <surname>Patel</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Doddapattar</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ghatge</surname></string-name>, <string-name><given-names>G.D.</given-names> <surname>Flora</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Jain</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Thedens</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Olalde</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Kumskova</surname></string-name>, <string-name><given-names>E.C.</given-names> <surname>Leira</surname></string-name>, and <string-name><given-names>A.K.</given-names> <surname>Chauhan</surname></string-name>. <year>2022</year>. <article-title>PKM2 promotes neutrophil activation and cerebral thromboinflammation: therapeutic implications for ischemic stroke</article-title>. <source>Blood</source>. <volume>139</volume>:<fpage>1234</fpage>–<lpage>1245</lpage>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Faubert</surname>, <given-names>B.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Solmonson</surname></string-name>, and <string-name><given-names>R.J.</given-names> <surname>DeBerardinis</surname></string-name>. <year>2020</year>. <article-title>Metabolic reprogramming and cancer progression</article-title>. <source>Science</source>. <volume>368</volume>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><string-name><surname>Goldsmith</surname>, <given-names>J.R.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Fayngerts</surname></string-name>, and <string-name><given-names>Y.H.</given-names> <surname>Chen</surname></string-name>. <year>2017</year>. <article-title>Regulation of inflammation and tumorigenesis by the TIPE family of phospholipid transfer proteins</article-title>. <source>Cell Mol Immunol</source>. <volume>14</volume>:<fpage>482</fpage>–<lpage>487</lpage>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><string-name><surname>Guo</surname>, <given-names>D.</given-names></string-name>, <string-name><given-names>Y.</given-names> <surname>Tong</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Meng</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Du</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Luo</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Xiao</surname></string-name>, <string-name><given-names>H.</given-names> <surname>He</surname></string-name>, <string-name><given-names>X.</given-names> <surname>He</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Fang</surname></string-name>, and <string-name><given-names>Z.</given-names> <surname>Lu</surname></string-name>. <year>2022</year>. <article-title>Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IkappaBalpha</article-title>. <source>Cell Metab</source>. <volume>34</volume>:<fpage>1312</fpage>–<lpage>1324 e1316</lpage>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>Han</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>Z.T.</given-names> <surname>Schug</surname></string-name>, and <string-name><given-names>A.E.</given-names> <surname>Aplin</surname></string-name>. <year>2021</year>. <article-title>Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma</article-title>. <source>Trends Cancer</source>. <volume>7</volume>:<fpage>671</fpage>–<lpage>681</lpage>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Hu</surname>, <given-names>Y.</given-names></string-name>, and <string-name><given-names>G.K.</given-names> <surname>Smyth</surname></string-name>. <year>2009</year>. <article-title>ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays</article-title>. <source>J Immunol Methods</source>. <volume>347</volume>:<fpage>70</fpage>–<lpage>78</lpage>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><string-name><surname>Icard</surname>, <given-names>P.</given-names></string-name>, <string-name><given-names>L.</given-names> <surname>Simula</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Fournel</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Leroy</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Lupo</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Damotte</surname></string-name>, <string-name><given-names>M.C.</given-names> <surname>Charpentier</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Durdux</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Loi</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Schussler</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Chassagnon</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Coquerel</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Lincet</surname></string-name>, <string-name><given-names>V.</given-names> <surname>De Pauw</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Alifano</surname></string-name>. <year>2022</year>. <article-title>The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications</article-title>. <source>Drug Resist Updat</source>. <volume>63</volume>:<fpage>100852</fpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><string-name><surname>Li</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>X.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>J.R.</given-names> <surname>Goldsmith</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Shi</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Zamani</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wan</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Etwebi</surname></string-name>, <string-name><given-names>M.J.</given-names> <surname>Bou-Dargham</surname></string-name>, and <string-name><given-names>Y.H.</given-names> <surname>Chen</surname></string-name>. <year>2021</year>. <article-title>Decoupling tumor cell metastasis from growth by cellular pilot protein TNFAIP8</article-title>. <source>Oncogene</source>. <volume>40</volume>:<fpage>6456</fpage>–<lpage>6468</lpage>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Li</surname>, <given-names>N.</given-names></string-name>, <string-name><given-names>L.</given-names> <surname>Feng</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Kasembeli</surname></string-name>, <string-name><given-names>M.K.</given-names> <surname>Tran</surname></string-name>, <string-name><given-names>D.J.</given-names> <surname>Tweardy</surname></string-name>, <string-name><given-names>S.H.</given-names> <surname>Lin</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>Chen</surname></string-name>. <year>2016</year>. <article-title>PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2</article-title>. <source>Cell Rep</source>. <volume>15</volume>:<fpage>843</fpage>–<lpage>856</lpage>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>, <given-names>F.</given-names></string-name>, <string-name><given-names>F.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Hao</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zeng</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Jia</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>I.M.</given-names> <surname>Ong</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Gong</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Li</surname></string-name>, and <string-name><given-names>W.</given-names> <surname>Xu</surname></string-name>. <year>2017</year>. <article-title>PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis</article-title>. <source>Nat Cell Biol</source>. <volume>19</volume>:<fpage>1358</fpage>–<lpage>1370</lpage>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>, <given-names>F.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Gao</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Jia</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Donahue</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>I.M.</given-names> <surname>Ong</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Keles</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Li</surname></string-name>, and <string-name><given-names>W.</given-names> <surname>Xu</surname></string-name>. <year>2021</year>. <article-title>PKM2-TMEM33 axis regulates lipid homeostasis in cancer cells by controlling SCAP stability</article-title>. <source>EMBO J</source>. <volume>40</volume>:<fpage>e108065</fpage>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>Lou</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>X.</given-names> <surname>Tian</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Han</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Y.H.</given-names> <surname>Chen</surname></string-name>, and <string-name><given-names>H.</given-names> <surname>Wang</surname></string-name>. <year>2022</year>. <article-title>TNFAIP8 protein functions as a tumor suppressor in inflammation-associated colorectal tumorigenesis</article-title>. <source>Cell Death Dis</source>. <volume>13</volume>:<fpage>311</fpage>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Luo</surname>, <given-names>W.</given-names></string-name>, <string-name><given-names>H.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Chang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zhong</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Knabel</surname></string-name>, <string-name><given-names>R.</given-names> <surname>O’Meally</surname></string-name>, <string-name><given-names>R.N.</given-names> <surname>Cole</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Pandey</surname></string-name>, and <string-name><given-names>G.L.</given-names> <surname>Semenza</surname></string-name>. <year>2011</year>. <article-title>Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1</article-title>. <source>Cell</source>. <volume>145</volume>:<fpage>732</fpage>–<lpage>744</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Malekan</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>M.A.</given-names> <surname>Ebrahimzadeh</surname></string-name>, and <string-name><given-names>F.</given-names> <surname>Sheida</surname></string-name>. <year>2021</year>. <article-title>The role of Hypoxia-Inducible Factor-1alpha and its signaling in melanoma</article-title>. <source>Biomed Pharmacother</source>. <volume>141</volume>:<fpage>111873</fpage>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Morgan</surname>, <given-names>H.P.</given-names></string-name>, <string-name><given-names>F.J.</given-names> <surname>O’Reilly</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Wear</surname></string-name>, <string-name><given-names>J.R.</given-names> <surname>O’Neill</surname></string-name>, <string-name><given-names>L.A.</given-names> <surname>Fothergill-Gilmore</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Hupp</surname></string-name>, and <string-name><given-names>M.D.</given-names> <surname>Walkinshaw</surname></string-name>. <year>2013</year>. <article-title>M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation</article-title>. <source>Proc Natl Acad Sci U S A</source>. <volume>110</volume>:<fpage>5881</fpage>–<lpage>5886</lpage>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Niture</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>X.</given-names> <surname>Dong</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Arthur</surname></string-name>, <string-name><given-names>U.</given-names> <surname>Chimeh</surname></string-name>, <string-name><given-names>S.S.</given-names> <surname>Niture</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Zheng</surname></string-name>, and <string-name><given-names>D.</given-names> <surname>Kumar</surname></string-name>. <year>2018</year>. <article-title>Oncogenic Role of Tumor Necrosis Factor alpha-Induced Protein 8 (TNFAIP8)</article-title>. <source>Cells</source>. <volume>8</volume>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Niture</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Lin</surname></string-name>, <string-name><given-names>J.O.</given-names> <surname>Odera</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Moore</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhe</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Suy</surname></string-name>, <string-name><given-names>S.P.</given-names> <surname>Collins</surname></string-name>, and <string-name><given-names>D.</given-names> <surname>Kumar</surname></string-name>. <year>2021</year>. <article-title>TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation</article-title>. <source>Int J Biochem Cell Biol</source>. <volume>130</volume>:<fpage>105885</fpage>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><string-name><surname>Niu</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>W.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Liang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Yao</surname></string-name>, <string-name><given-names>R.H.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>Z.S.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>H.F.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>F.Y.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>S.H.</given-names> <surname>Pei</surname></string-name>, <string-name><given-names>W.Q.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Fang</surname></string-name>, and <string-name><given-names>S.Q.</given-names> <surname>Xie</surname></string-name>. <year>2020</year>. <article-title>EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3</article-title>. <source>Sci Signal</source>. <volume>13</volume>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><string-name><surname>Niu</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>Z.</given-names> <surname>Lin</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Wan</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Yan</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Liang</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Zhan</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Bu</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>W.</given-names> <surname>He</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Lu</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Wan</surname></string-name>. <year>2021</year>. <article-title>Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia</article-title>. <source>Hepatology</source>. <volume>74</volume>:<fpage>1461</fpage>–<lpage>1479</lpage>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>Novoyatleva</surname>, <given-names>T.</given-names></string-name>, <string-name><given-names>N.</given-names> <surname>Rai</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Weissmann</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Grimminger</surname></string-name>, <string-name><given-names>H.A.</given-names> <surname>Ghofrani</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Seeger</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Gall</surname></string-name>, and <string-name><given-names>R.T.</given-names> <surname>Schermuly</surname></string-name>. <year>2019</year>. <article-title>Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?</article-title> <source>Am J Respir Crit Care Med</source>. <volume>200</volume>:<fpage>1550</fpage>–<lpage>1554</lpage>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Ouyang</surname>, <given-names>X.</given-names></string-name>, <string-name><given-names>S.N.</given-names> <surname>Han</surname></string-name>, <string-name><given-names>J.Y.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Dioletis</surname></string-name>, <string-name><given-names>B.T.</given-names> <surname>Nemeth</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Pacher</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Feng</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Bataller</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Cabezas</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Starkel</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Caballeria</surname></string-name>, <string-name><given-names>R.L.</given-names> <surname>Pongratz</surname></string-name>, <string-name><given-names>S.Y.</given-names> <surname>Cai</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Schnabl</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Hoque</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>W.H.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Garcia-Martinez</surname></string-name>, <string-name><given-names>F.S.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Gao</surname></string-name>, <string-name><given-names>N.J.</given-names> <surname>Torok</surname></string-name>, <string-name><given-names>R.G.</given-names> <surname>Kibbey</surname></string-name>, and <string-name><given-names>W.Z.</given-names> <surname>Mehal</surname></string-name>. <year>2018</year>. <article-title>Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1alpha Transactivation in Steatohepatitis</article-title>. <source>Cell Metab</source>. <volume>27</volume>:<fpage>339</fpage>–<lpage>350 e333</lpage>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><string-name><surname>Padmavathi</surname>, <given-names>G.</given-names></string-name>, <string-name><given-names>K.</given-names> <surname>Banik</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Monisha</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Bordoloi</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Shabnam</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Arfuso</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Sethi</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Fan</surname></string-name>, and <string-name><given-names>A.B.</given-names> <surname>Kunnumakkara</surname></string-name>. <year>2018</year>. <article-title>Novel tumor necrosis factor-alpha induced protein eight (TNFAIP8/TIPE) family: Functions and downstream targets involved in cancer progression</article-title>. <source>Cancer Lett</source>. <volume>432</volume>:<fpage>260</fpage>–<lpage>271</lpage>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><string-name><surname>Pang</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ji</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Ye</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Lu</surname></string-name>, and <string-name><given-names>C.</given-names> <surname>Ji</surname></string-name>. <year>2020</year>. <article-title>TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1</article-title>. <source>J Exp Clin Cancer Res</source>. <volume>39</volume>:<fpage>158</fpage>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>Puckett</surname>, <given-names>D.L.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Alquraishi</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Chowanadisai</surname></string-name>, and <string-name><given-names>A.</given-names> <surname>Bettaieb</surname></string-name>. <year>2021</year>. <article-title>The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs</article-title>. <source>Int J Mol Sci</source>. <volume>22</volume>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><string-name><surname>Valentini</surname>, <given-names>G.</given-names></string-name>, <string-name><given-names>L.R.</given-names> <surname>Chiarelli</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Fortin</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Dolzan</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Galizzi</surname></string-name>, <string-name><given-names>D.J.</given-names> <surname>Abraham</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Bianchi</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Zanella</surname></string-name>, and <string-name><given-names>A.</given-names> <surname>Mattevi</surname></string-name>. <year>2002</year>. <article-title>Structure and function of human erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia</article-title>. <source>J Biol Chem</source>. <volume>277</volume>:<fpage>23807</fpage>–<lpage>23814</lpage>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>, <given-names>H.J.</given-names></string-name>, <string-name><given-names>Y.J.</given-names> <surname>Hsieh</surname></string-name>, <string-name><given-names>W.C.</given-names> <surname>Cheng</surname></string-name>, <string-name><given-names>C.P.</given-names> <surname>Lin</surname></string-name>, <string-name><given-names>Y.S.</given-names> <surname>Lin</surname></string-name>, <string-name><given-names>S.F.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>C.C.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Izumiya</surname></string-name>, <string-name><given-names>J.S.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>H.J.</given-names> <surname>Kung</surname></string-name>, and <string-name><given-names>W.C.</given-names> <surname>Wang</surname></string-name>. <year>2014</year>. <article-title>JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism</article-title>. <source>Proc Natl Acad Sci U S A</source>. <volume>111</volume>:<fpage>279</fpage>–<lpage>284</lpage>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><string-name><surname>Wei</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Lu</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mei</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Han</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Yao</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Ding</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Ding</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Xiao</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Hu</surname></string-name>. <year>2020</year>. <article-title>Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection</article-title>. <source>Nat Commun</source>. <volume>11</volume>:<fpage>941</fpage>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><string-name><surname>Weinstein</surname>, <given-names>A.G.</given-names></string-name>, <string-name><given-names>I.</given-names> <surname>Godet</surname></string-name>, and <string-name><given-names>D.M.</given-names> <surname>Gilkes</surname></string-name>. <year>2022</year>. <article-title>The rise of viperin: the emerging role of viperin in cancer progression</article-title>. <source>J Clin Invest</source>. <volume>132</volume>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><string-name><surname>Yang</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Lou</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Liu</surname></string-name>, and <string-name><given-names>P.</given-names> <surname>Zhao</surname></string-name>. <year>2022</year>. <article-title>TIPE1 inhibits osteosarcoma tumorigenesis and progression by regulating PRMT1 mediated STAT3 arginine methylation</article-title>. <source>Cell Death Dis</source>. <volume>13</volume>:<fpage>815</fpage>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><string-name><surname>Yang</surname>, <given-names>W.</given-names></string-name>, <string-name><given-names>Y.</given-names> <surname>Zheng</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Xia</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Ji</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Lyssiotis</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Aldape</surname></string-name>, <string-name><given-names>L.C.</given-names> <surname>Cantley</surname></string-name>, and <string-name><given-names>Z.</given-names> <surname>Lu</surname></string-name>. <year>2012</year>. <article-title>ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect</article-title>. <source>Nat Cell Biol</source>. <volume>14</volume>:<fpage>1295</fpage>–<lpage>1304</lpage>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><string-name><surname>Yang</surname>, <given-names>Y.C.</given-names></string-name>, <string-name><given-names>M.H.</given-names> <surname>Chien</surname></string-name>, <string-name><given-names>H.Y.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>Y.C.</given-names> <surname>Chang</surname></string-name>, <string-name><given-names>C.K.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>W.J.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>T.C.</given-names> <surname>Kuo</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Hsiao</surname></string-name>, <string-name><given-names>K.T.</given-names> <surname>Hua</surname></string-name>, and <string-name><given-names>T.Y.</given-names> <surname>Cheng</surname></string-name>. <year>2018</year>. <article-title>Nuclear translocation of PKM2/AMPK complex sustains cancer stem cell populations under glucose restriction stress</article-title>. <source>Cancer Lett</source>. <volume>421</volume>:<fpage>28</fpage>–<lpage>40</lpage>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>, <given-names>Z.</given-names></string-name>, <string-name><given-names>X.</given-names> <surname>Deng</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Sun</surname></string-name>, and <string-name><given-names>F.</given-names> <surname>Chen</surname></string-name>. <year>2019</year>. <article-title>PKM2, function and expression and regulation</article-title>. <source>Cell Biosci</source>. <volume>9</volume>:<fpage>52</fpage>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><string-name><surname>Zhao</surname>, <given-names>P.</given-names></string-name>, <string-name><given-names>X.</given-names> <surname>Pang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Yin</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Zhai</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Xiang</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Feng</surname></string-name>, and <string-name><given-names>W.</given-names> <surname>Xu</surname></string-name>. <year>2019</year>. <article-title>TIPE1 promotes cervical cancer progression by repression of p53 acetylation and is associated with poor cervical cancer outcome</article-title>. <source>Carcinogenesis</source>. <volume>40</volume>:<fpage>592</fpage>–<lpage>599</lpage>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname>, <given-names>Q.</given-names></string-name>, <string-name><given-names>Y.</given-names> <surname>Yin</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Gao</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Weng</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Atyah</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Shen</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Ye</surname></string-name>, <string-name><given-names>C.W.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>M.C.</given-names> <surname>Hung</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Dong</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Zhou</surname></string-name>, and <string-name><given-names>N.</given-names> <surname>Ren</surname></string-name>. <year>2022</year>. <article-title>GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism</article-title>. <source>Redox Biol</source>. <volume>56</volume>:<fpage>102458</fpage>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname>, <given-names>Z.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Sahin</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>J.J.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Songyang</surname></string-name>, and <string-name><given-names>D.</given-names> <surname>Yu</surname></string-name>. <year>2018</year>. <article-title>Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells</article-title>. <source>Cancer Res</source>. <volume>78</volume>:<fpage>2248</fpage>–<lpage>2261</lpage>.</mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname>, <given-names>B.</given-names></string-name>, <string-name><given-names>W.</given-names> <surname>Zhong</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Cao</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Pan</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zheng</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Feng</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Luo</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Lu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Xiao</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Lin</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Lai</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Du</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Yi</surname></string-name>, and <string-name><given-names>D.</given-names> <surname>Yan</surname></string-name>. <year>2022</year>. <article-title>Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice</article-title>. <source>Sci Transl Med</source>. <volume>14</volume>:<fpage>eabh2548</fpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92741.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Postovit</surname>
<given-names>Lynne-Marie</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Queens University</institution>
</institution-wrap>
<city>Kingston</city>
<country>Canada</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>important</bold> study investigates the molecular mechanisms underpinning how the tumor necrosis factor alpha-induced protein, TIPE, regulates aerobic glycolysis to promote tumor growth in melanoma. Data using multiple independent approaches provide new insights into the molecular mechanisms underpinning aerobic glycolysis, also known as the Warburg Effect, in melanoma cells. The claims of the authors are <bold>solid</bold>, although more in-depth metabolic assays as well as the inclusion of melanoma patient survival analysis in TIPE high and low tumors would strengthen the study. The work will be of interest to biomedical researchers working in cancer and metabolism.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92741.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>
Tian et al. describe how TIPE regulates melanoma progression, stemness, and glycolysis. The authors link high TIPE expression to increased melanoma cell proliferation and tumor growth. TIPE causes dimerization of PKM2, as well as translocation of PKM2 to the nucleus, thereby activating HIF-1alpha. TIPE promotes the phosphorylation of S37 on PKM2 in an ERK-dependent manner. TIPE is shown to increase stem-like phenotype markers. The expression of TIPE is positively correlated with the levels of PKM2 Ser37 phosphorylation in murine and clinical tissue samples. Taken together, the authors demonstrate how TIPE impacts melanoma progression, stemness, and glycolysis through dimeric PKM2 and HIF-1alpha crosstalk.</p>
<p>Strengths:</p>
<p>
The authors manipulated TIPE expression using both shRNA and overexpression approaches throughout the manuscript. Using these models, they provide strong evidence of the involvement of TIPE in mediating PKM2 Ser37 phosphorylation and dimerization. The authors also used mutants of PKM2 at S37A to block its interaction with TIPE and HIF-1alpha. In addition, an ERK inhibitor (U0126) was used to block the phosphorylation of Ser37 on PKM2. The authors show how dimerization of PKM2 by TIPE causes nuclear import of PKM2 and activation of HIF-1alpha and target genes. Pyridoxine was used to induce PKM2 dimer formation, while TEPP-46 was used to suppress PKM2 dimer formation. TIPE maintains stem cell phenotypes by increasing the expression of stem-like markers. Furthermore, the relationship between TIPE and Ser37 PKM2 was demonstrated in murine and clinical tissue samples.</p>
<p>Weaknesses:</p>
<p>
The evaluation of how TIPE causes metabolic reprogramming can be better assessed using isotope tracing experiments and improved bioenergetic analysis.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.92741.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>In this article, Tian et al present a convincing analysis of the molecular mechanisms underpinning TIPE-mediated regulation of glycolysis and tumor growth in melanoma. The authors begin by confirming TIPE expression in melanoma cell lines and identify &quot;high&quot; and &quot;low&quot; expressing models for functional analysis. They show that TIPE depletion slows tumour growth in vivo, and using both knockdown and over-expression approaches, show that this is associated with changes in glycolysis in vitro. Compelling data using multiple independent approaches is presented to support an interaction between TIPE and the glycolysis regulator PKM2, and the over-expression of TIPE-promoted nuclear translocation of PKM2 dimers. Mechanistically, the authors also demonstrate that PKM2 is required for TIPE-mediated activation of HIF1a transcriptional activity, as assessed using an HRE-promoter reporter assay, and that TIPE-mediated PKM2 dimerization is p-ERK dependent. Finally, the dependence of TIPE activity on PKM2 dimerization was demonstrated on tumor growth in vivo and in the regulation of glycolysis in vitro, and ectopic expression of HIF1a could rescue the inhibition of PKM2 dimerization in TIPE overexpressing cells and reduced induction of general cancer stem cell markers, showing a clear role for HIF1a in this pathway. The main conclusions of this paper are well supported by data, but some aspects of the experiments need clarification and some data panels are difficult to read and interpret as currently presented.</p>
<p>The detailed mechanistic analysis of TIPE-mediated regulation of PKM2 to control aerobic glycolysis and tumor growth is a major strength of the study and provides new insights into the molecular mechanisms that underpin the Warburg effect in cancer cells. However, despite these strengths, some weaknesses were noted, which if addressed will further strengthen the study.</p>
<p>1. The analysis of patient samples should be expanded to more directly measure the relationship between TIPE levels and melanoma patient outcome and progression (primary vs metastasis), to build on the association between TIPE levels and proliferation (Ki67) and hypoxia gene sets that are currently shown.</p>
<p>2. The duration of the in vivo experiments was not clearly defined in the figures, however, it was clear from the tumor volume measurements that they ended well before standard ethical endpoints in some of the experiments. A rationale for this should be provided because longer-duration experiments might significantly change the interpretation of the data. For example, does TIPE depletion transiently reduce or lead to sustained reductions in tumor growth?</p>
<p>3. The analysis of general cancer stem cell markers is solid and interesting, however inclusion of neural crest stem cell markers that are more relevant to melanoma biology would greatly strengthen this aspect of the study.</p>
<p>4. The authors should take care that all data panels are clearly readable in the figures to facilitate appropriate interpretation by the reader.</p>
</body>
</sub-article>
</article>